CN111450183A - 一种治疗高血脂、动脉粥样硬化的中药组合物 - Google Patents
一种治疗高血脂、动脉粥样硬化的中药组合物 Download PDFInfo
- Publication number
- CN111450183A CN111450183A CN202010464486.XA CN202010464486A CN111450183A CN 111450183 A CN111450183 A CN 111450183A CN 202010464486 A CN202010464486 A CN 202010464486A CN 111450183 A CN111450183 A CN 111450183A
- Authority
- CN
- China
- Prior art keywords
- parts
- atherosclerosis
- treating hyperlipidemia
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 19
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 26
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 12
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 8
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 8
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 7
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 7
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 7
- 235000011477 liquorice Nutrition 0.000 claims abstract description 7
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 6
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 6
- 244000170916 Paeonia officinalis Species 0.000 claims abstract description 6
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 claims abstract description 3
- 240000001398 Typha domingensis Species 0.000 claims abstract 2
- 239000002775 capsule Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 17
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 29
- 235000012000 cholesterol Nutrition 0.000 description 9
- 210000001367 artery Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 241000233948 Typha Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- 239000005717 Laminarin Substances 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- -1 lipid peroxide Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 241000748223 Alisma Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 101710129448 Glucose-6-phosphate isomerase 2 Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 201000001962 aortic atherosclerosis Diseases 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000009609 fructus phyllanthi Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
本发明公开了一种治疗高血脂、动脉粥样硬化中药组合物，是由下列重量份的原料药组成：甘草3‑6份；蒲黄、女贞子、泽泻、赤芍、余甘子、昆布6‑12份；绞股蓝15‑30份。本发明具有治疗效果显著、治疗周期短、无毒副作用等特点。
Description
技术领域
本发明属于中药技术领域，尤其是涉及一种治疗高血脂、动脉粥样硬化的中药组合物。
背景技术
由于在动脉内膜积聚的脂质外观呈黄色粥样，因此称为动脉粥样硬化。脂质代谢障碍为动脉粥样硬化的病变基础，其特点是受累动脉病变从内膜开始，一般先有脂质和复合糖类积聚、出血及血栓形成，进而纤维组织增生及钙质沉着，并有动脉中层的逐渐蜕变和钙化，导致动脉壁增厚变硬、血管腔狭窄。病变常累及大中肌性动脉，一旦发展到足以阻塞动脉腔，则该动脉所供应的组织或器官将缺血或坏死。
动脉粥样硬化是多因素共同作用引起的主要危险因素有高血压、高血脂和大量吸烟，还有糖尿病、肥胖和遗传因素等。
西医对于重度（70%以上）狭窄或闭塞动脉进行再通、重建或旁路移植等外科手术，或者采取血管腔内放置支架等介入治疗。而对中度以下狭窄多采用药物（他汀类）预防斑块继续生长。
西药不能缩小、消除斑块。长期服用后往往引起肝肾损害和胃部不适、胃溃疡甚至诱发脑出血等疾病，且疗效不甚理想。
发明内容
本发明的目的在于改进已有技术的不足而提供一种高血脂、动脉粥样硬化的中药组合物，具有治疗效果显著、治疗周期短、无毒副作用等特点。
中医认粥样斑块形成是痰浊、瘀血凝聚而成。中医治疗动脉粥样硬化斑块多以深入机理，针对病根为主，活血化痰，从而取得满意的疗效。
基于上述理论，本发明的技术方案是：一种内服用于治疗高血脂、动脉粥样硬化的中药，由下列重量份的原料药组成：甘草3-6份；蒲黄、女贞子、泽泻、赤芍、余甘子、昆布6-12份；绞股蓝15-30份。
在一个优选的实施方案中，所述治疗咽喉炎和扁桃体炎的中药组合物由下列重量份的原料药组成：甘草6份；蒲黄、女贞子、泽泻、赤芍、余甘子、昆布12份；绞股蓝30份。
其中，生蒲黄:甘，平。归肝、心包经。止血，化瘀，通淋。
蒲黄降血脂及抗动脉粥样硬化，是各种有效成分对不同环节的综合作用所致。蒲黄能影响体内胆固醇代谢，抑制肠道吸收胆固醇、增加胆固醇排泄，防止血清胆固醇水平增高。蒲黄除可使急、慢性高血脂症血清总胆固醇降低外，还可使高密度脂蛋白胆固醇升高、降低血小板粘附和聚集性，前列环素（PCI2）显着下降，血栓素A2（TXA2）/PGI2升高，使两者比值维持正常。蒲黄对血管内皮细胞有保护作用，能强烈的刺激动脉内皮细胞产生PGI2和tPA（纤溶酶原激活物）活性，使主动脉壁胆固醇含量减少，主动脉内皮完整光滑，内膜下层正常并能抑制粥样硬化斑块形成，抑制ADP诱导血小板聚集。蒲黄能扩张心肌内小动脉，使血流增加，代谢旺盛，心肌营养改善，斑块形成较少。
绞股蓝：味苦；微甘；性凉。归肺；脾；肾经。清热解毒，止咳祛痰，补虚。用于白细胞减少症；高脂血症等。绞股蓝能明显对抗血清总胆固醇升高，绞股蓝总皂甙明显降低低密度脂蛋白水平，能明显降低动脉粥样硬化指数。
泽泻：甘，寒。归肾、膀胱经。利小便，清湿热。用于高血脂等。泽泻的脂溶性部份对高胆固醇血症有明显的降胆固醇作用和抗动脉粥样硬化作用。
女贞子：甘、苦，凉。归肝、肾经。滋补肝肾，明目乌发。
女贞子明显降低血清总胆甾醇、过氧化脂质、动脉壁总胆甾醇含量，并使主动脉脂质斑块及冠状动脉粥样斑块形成消减。
甘草：甘，平。归心、肺、脾、胃经 。补脾益气，清热解毒，祛痰止咳，缓急止痛，调和诸药。甘草能使动脉粥样硬化患者的胆固醇、脂蛋白和β-脂蛋白甘油三酯明显降低，脂质系统和肝功能改善，粥样硬化程度减轻，阻断大动脉及冠状动脉粥样硬化的病理进程。
赤芍：味苦，微寒。归肝经。清热凉血，散瘀止痛。赤芍使高脂血血浆总胆固醇、三酰甘油、低密度脂蛋白胆固醇、极低密度脂蛋白胆固醇显着降低；高密度脂蛋白胆固醇显着升高。同时改善脂蛋白组分比值、使高脂血症所致血栓烷A2/前列环素比值趋于正常。此外还可抑制血小板聚集，降低血浆过氧化脂质，激活腺苷酸环化酶而增加动脉壁内环磷酸腺苷cAMP浓度减少动脉壁脂质、钙和磷脂沉积于动脉壁及主动脉斑块面积。
余甘子：甘、酸、涩、凉。归肺、胃经。清热凉血，消食健胃，生津止咳。余甘子是较好的天然降脂药物，疗效高于维生素E，并明显抑制主动脉内膜斑块的形成，可治疗微血管病变和神经系统并发症。余甘子能干扰胆固醇的吸收，使血清总胆固醇、甘油三脂、磷脂及低密度脂蛋白胆固醇水平分别降低 80%，66%，77%及 90%，并能加速胆固醇及磷脂从粪便中排泄，对高胆固醇血症疗效最好。
昆布：咸，寒。归肝、胃、肾经。软坚散结，消痰，利水。
海带多糖能明显地抑制高血脂、血清总胆固醇、甘油三酯的含量上升，并能减少主动脉内膜粥样斑块的形成及发展。海带多糖同时具有降血脂和抗凝血作用。
本发明是由中国传统的中草药制成，根据中医辨证论治及现代医学的若干原则，以某些成分确定、功效明晰的天然提取物的有序配伍，组合成了治疗高血脂、动脉粥样硬化的中药组合物。
本发明安全可靠无明显毒副反应，不伤脾胃，便于患者长期坚持服用，能够安全、原位消除动脉斑块，清除血流粘稠缓慢、血脂沉淀、血管内皮损伤等动脉斑块形成内因，从而有效预防动脉斑块的再生和复发。
本发明的中药组合物药味数目少，原料易得，工艺简单，成本低，效率高，有利于制药企业进行药品生产、质量控制；产品价格低，易于被患者接受。
本发明的中药组合物治高血脂、动脉粥样硬化效果显著，临床实验结果显示，用本药方施治，每日一剂，水煎100-150ml，分成两份，早晚各一份服用，一个月为一个疗程，5-6个疗程治愈率为86％，总有效率为100％。
本发明治疗费用相对低廉，远远低于西医的治疗费用。
本发明还提供了一种由上述治疗 的中药组合物制成的口服制剂，所述口服制 剂包括口服液、片剂、胶囊剂、丸剂等，优选剂型为片剂和胶囊剂，一日一剂，分早晚两次服用。
本发明的中药组合物可以制备成多种剂型。例如，将煎煮后的药液杀菌消毒后装袋，制成口服液；或者将煎煮后的药液进行浓缩，烘干后，加入医学上可接收的辅料，然后制成片剂、胶囊剂、丸剂等。
所述医学上可接收的辅料包括淀粉、糊精、羧甲基纤维素钠、聚乙二醇、磷酸氢钙、海藻酸钠、山梨酸钾等。
以上所述，仅是本发明的较佳实施例而已，并非对本发明作任何形式上的限制，本领域技术人员利用上述揭示的技术内容做出些许简单修改、等同变化或修饰，均落在本发明的保护范围内。
Claims (4)
1.一种治疗高血脂、动脉粥样硬化的中药组合物，其特征在于，该中药组合物包括：甘草3-6份；蒲黄、女贞子、泽泻、赤芍、余甘子、昆布6-12份；绞股蓝15-30份。
2.根据权利要求1所述的一种治疗高血脂、动脉粥样硬化的中药，其特征是由下列重量份的原料药组成：甘草6份；蒲黄、女贞子、泽泻、赤芍、余甘子、昆布12份；绞股蓝30份。
3.一种治疗高血脂、动脉粥样硬化的的口服制剂，其特征是由权利要求1或2中任一项所述的中药组合物制成。
4.根据权利要求3所述的一种治疗高血脂、动脉粥样硬化的口服制剂，其特征是包括口服液、片剂、胶囊剂、丸剂，优选胶囊剂和片剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010464486.XA CN111450183A (zh) | 2020-05-28 | 2020-05-28 | 一种治疗高血脂、动脉粥样硬化的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010464486.XA CN111450183A (zh) | 2020-05-28 | 2020-05-28 | 一种治疗高血脂、动脉粥样硬化的中药组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111450183A true CN111450183A (zh) | 2020-07-28 |
Family
ID=71671402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010464486.XA Withdrawn CN111450183A (zh) | 2020-05-28 | 2020-05-28 | 一种治疗高血脂、动脉粥样硬化的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111450183A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423413A (zh) * | 2012-01-04 | 2012-04-25 | 陈伯明 | 治疗高血脂、脂肪肝和防止动脉粥样硬化的药及其用途 |
| CN103041065A (zh) * | 2012-12-03 | 2013-04-17 | 马千里 | 一种降血脂的中药组合物 |
| CN104055966A (zh) * | 2014-07-08 | 2014-09-24 | 福建中医药大学 | 泽泻降脂浓缩丸 |
| CN105169214A (zh) * | 2015-07-15 | 2015-12-23 | 济南大学 | 一种治疗动脉粥样硬化的中药组合物及其制备方法 |
-
2020
- 2020-05-28 CN CN202010464486.XA patent/CN111450183A/zh not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423413A (zh) * | 2012-01-04 | 2012-04-25 | 陈伯明 | 治疗高血脂、脂肪肝和防止动脉粥样硬化的药及其用途 |
| CN103041065A (zh) * | 2012-12-03 | 2013-04-17 | 马千里 | 一种降血脂的中药组合物 |
| CN104055966A (zh) * | 2014-07-08 | 2014-09-24 | 福建中医药大学 | 泽泻降脂浓缩丸 |
| CN105169214A (zh) * | 2015-07-15 | 2015-12-23 | 济南大学 | 一种治疗动脉粥样硬化的中药组合物及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 林育华 等: "药食两用植物", vol. 1, 复旦大学出版社, pages: 185 - 188 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102000299B (zh) | 一种治疗高脂血症的药物 | |
| CN105412623A (zh) | 治疗脂肪肝、前列腺炎、肾痛肾炎、高血压及糖尿病的药物 | |
| CN105169214A (zh) | 一种治疗动脉粥样硬化的中药组合物及其制备方法 | |
| CN104758806A (zh) | 一种治疗冠心病的煎膏剂及其制备方法 | |
| CN104740541A (zh) | 一种保肝解毒恢复肝功能的保健中药粉 | |
| CN104825801A (zh) | 一种预防和治疗心脑血管疾病的中药制剂 | |
| CN108524673A (zh) | 一种中药组合物及其应用 | |
| CN101804110B (zh) | 一种抗血栓和降血脂的中药制剂 | |
| CN104288464A (zh) | 一种治疗心脑血管疾病的中药 | |
| CN102552435B (zh) | 一种改善营养性贫血、增强免疫力功能的保健药物 | |
| CN111450183A (zh) | 一种治疗高血脂、动脉粥样硬化的中药组合物 | |
| CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
| CN102579688B (zh) | 菊麻降压中药制剂 | |
| CN102698185B (zh) | 一种治疗高血脂症的藏药及其制备方法 | |
| CN112089784A (zh) | 中药组合物在制备预防、治疗动脉粥样硬化所致疾病的药物中的应用 | |
| CN111494512A (zh) | 一种治疗冠心症、心绞痛的中药组合物 | |
| CN1248684C (zh) | 治疗心脑血管疾病的中药散剂及其制备方法 | |
| CN110898195A (zh) | 一种调理脑中风的中药食疗制品及其制备方法 | |
| CN109771567A (zh) | 一种中草药扶正化瘀排毒化肿瘤的配方 | |
| CN104606511A (zh) | 一种预防微创治疗腰椎间盘突出症术后反跳现象的中药 | |
| CN103961603B (zh) | 一种降血脂通脉的中药制剂 | |
| CN115252700B (zh) | 用于治疗颈源性耳鸣的中药组合物、药物及其制备方法 | |
| CN101244209B (zh) | 预防或治疗心脑血管疾病的药物 | |
| CN102755520B (zh) | 一种治疗心血管疾病的中药制剂 | |
| CN105477171A (zh) | 一种用于治疗高脂血症的胶囊及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200728 |
|
| WW01 | Invention patent application withdrawn after publication |